AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 529461: 4a-methyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydro-2H-naphthalene-1-carbaldehyde

Chemical compound data from PubChem database. IUPAC Name: 4a-methyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydro-2H-naphthalene-1-carbaldehyde. Molecular Formula: C15H22O. Molecular Weight: 218.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528229: 1-(2-Hydroxyethylthio)-2-(2-vinylthioethoxy)ethane

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(2-ethenylsulfanylethoxy)ethylsulfanyl]ethanol. Molecular Formula: C8H16O2S2. Molecular Weight: 208.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528587: tert-Butyl(dimethyl)silyl stearate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] octadecanoate. Molecular Formula: C24H50O2Si. Molecular Weight: 398.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400701-T1: [Translated] ROADWAY FOR DECLARING AND/OR ACCELERATING A VEHICLE, INCLUDING AN AIRCRAFT

A method for slowing a vehicle traveling over a movable surface in a direction of travel where the vehicle has a first wheel and at least a second wheel offset from the first wheel in a direction opposite to the direction of travel. The method including: deploying the movable surface to an open position; moving the movable surface to a closed position due to the weight exerted on the movable surface by the first wheel of the vehicle as it travels over the movable surface; locking the movable surface in the closed position to convert at least a portion of a kinetic energy of the vehicle into potential energy to slow the vehicle; and redeploying the movable surface to the open position such that at least the moving can be repeated due to the weight exerted on the movable surface by the second wheel of the vehicle.
Compound 526399: 2-Bromo,1,3,4,6,7,8,9-heptachloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 2-bromo-1,3,4,6,7,8,9-heptachlorodibenzo-p-dioxin. Molecular Formula: C12BrCl7O2. Molecular Weight: 504.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Expression of nm23-H1 gene product in esophageal squamous cell carcinoma and its association with vessel invasion and survival

Background
          We assessed the nm23-H1 gene product expression and its relationship with lymphatic and blood vessel invasion in patients with esophageal squamous cell carcinoma.
        
        
          Methods
          Formalin-fixed and paraffin-embedded tissue sections from 45 patients who were treated surgically were used in this study. Pathologists graded lymphatic and blood vessel invasion in each of the tissue samples. Expression of nm23-Hl gene product was determined using a specific monoclonal antibody.
        
        
          Results
          Expression of nm23-H1 gene product was present in 17 (37.8%) cases. We found an inverse correlation between nm23-H1 gene product expression and lymphatic vessel invasion, whereas no correlation between nm23-H1 gene product expression and blood vessel invasion. Overall survival rate was not different between nm23-H1 gene product positive and negative patients (p = 0.21). However, reduced expression of nm23-H1 gene product was associated with shorter overall survival in patients with involved lymph nodes (p < 0.05), but not in patients without involved lymph nodes (p = 0.87).
        
        
          Conclusions
          In patients with esophageal squamous cell carcinoma, there appears to be an inverse relationship between nm23-H1 gene product expression and lymphatic vessel invasion. Furthermore, nm23-H1 gene product expression might be a prognostic marker in patients with involved lymph nodes. Our data does not demonstrate any correlation between nm23-H1 gene product expression and blood vessel invasion.
Patent AT-E399651-T1: [Translated] VALUE OR SECURITY DOCUMENT WITH A SWITCH

The invention relates to a valuable document or security document (1) that comprises one or more LED elements (2) as a security feature. The LED element (2) is supplied with power by an energy source (3) via lines (4) and (5). Energy source (3) is preferably a passive energy source, that is a solar cell or an antenna. The invention allows for the provision of public features or biometric data for the purpose of identification and/or authentication by personalization of the LED element (2).
The role of lumbar puncture in children with suspected central nervous system infection

Background
          The use of the lumbar puncture in the diagnosis of central nervous system infection in acutely ill children is controversial. Recommendations have been published but it is unclear whether they are being followed.
        
        
          Methods
          The medical case notes of 415 acute medical admissions in a children's hospital were examined to identify children with suspected central nervous system infection and suspected meningococcal septicaemia. We determined whether lumbar punctures were indicated or contraindicated, whether they had been performed, and whether the results contributed to the patients' management.
        
        
          Results
          Fifty-two children with suspected central nervous system infections, and 43 with suspected meningococcal septicaemia were identified. No lumbar punctures were performed in patients with contraindications, but only 25 (53%) of 47 children with suspected central nervous system infection and no contraindications received a lumbar puncture. Lumbar puncture findings contributed to the management in 18 (72%) of these patients, by identifying a causative organism or excluding bacterial meningitis.
        
        
          Conclusion
          The recommendations for undertaking lumbar punctures in children with suspected central nervous system infection are not being followed because many children that should receive lumbar punctures are not getting them. When they are performed, lumbar puncture findings make a useful contribution to the patients' management.
Patent AT-E401366-T1: [Translated] POLYAMIDE FILM AND POLYAMIDE LAMINATE FILM

A biaxially oriented polyamide film showing an average dimensional change of not more than 3.0% and a difference between the smallest dimensional change and the largest dimensional change of not more than 2.0%, between before immersion in hot water at 95 DEG C and during the immersion, and an average dimensional change of not more than 4.0% and a difference between the smallest dimensional change and the largest dimensional change of not more than 2.0%, between the film without treatment and the film after withdrawal from said hot water; and a polyamide laminate film containing the film as a substrate layer. The films afforded by the present invention have superior properties and are industrially advantageous in a broad range of applications.
NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease (age <5 years), Serotype b

NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease (age <5 years), Serotype b - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
COVID-19 Hospital Admissions Over Time

<strong> As of 9/12/2024, we have resumed reporting on COVID-19 hospitalization data using a San Francisco specific dataset. These new data differ slightly from previous hospitalization data sources but the overall patterns and trends in hospitalizations remain consistent. You can access the previous data <u><a href="https://data.sfgov.org/Health-and-Social-Services/COVID-19-Hospitalizations-Over-Time/nxjg-bhem/about_data">here.</a></u> </strong>

<strong>A. SUMMARY</strong>
This dataset includes information on COVID+ hospital admissions for San Francisco residents into San Francisco hospitals. Specifically, the dataset includes the count and rate of COVID+ hospital admissions per 100,000. The data are reported by week.  

<strong>B. HOW THE DATASET IS CREATED</strong>
Hospital admission data is reported to the San Francisco Department of Public Health (SFDPH) via the COVID Hospital Data Repository (CHDR), a system created via health officer order <u><a href="https://www.sf.gov/sites/default/files/2022-03/Order-C19-16-Hospitals-Data.pdf">C19-16</a></u>. The data includes all San Francisco hospitals except for the San Francisco VA Medical Center.

San Francisco population estimates are pulled from a view based on the <u><a href="https://data.sfgov.org/Economy-and-Community/SFDPH-reporting-demographics-population-estimates/cedd-86uf"> San Francisco Population and Demographic Census dataset</a></u>. These population estimates are from the 2018-2022 5-year American Community Survey (ACS).

<strong>C. UPDATE PROCESS</strong>
Data updates weekly on Wednesday with data for the past Wednesday-Tuesday (one week lag). Data may change as more current information becomes available. 

<strong>D. HOW TO USE THIS DATASET</strong>
New admissions are the count of COVID+ hospital admissions among San Francisco residents to San Francisco hospitals by week. 

The admission rate per 100,000 is calculated by multiplying the count of admissions each week by 100,000 and dividing by the population estimate.

<strong>E. CHANGE LOG</strong>
Patent AT-E399600-T1: [Translated] POWDER APPLICATOR FOR CABLES

The hopper (2) contains the powder (20). A grid (9) closes the small hopper opening. An agitator is included inside. This is positioned to cause flow of powder through the grid, under gravity. No subsequent means of powder conveying is included in the applicator. Once through the grid, it flows under gravity to the cable components (5). An independent claim is included for the corresponding method.
Daptomycin

Daptomycin is an antibiotic medication used to treat serious bacterial infections, such as those in the skin, soft tissues, or bloodstream. It belongs to the lipopeptide class and is administered intravenously as a powder that is mixed into a solution before use. Manufactured by Fresenius Kabi USA, LLC, it comes in 500 mg vials. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E401795-T1: [Translated] THE ORAL ABSORPTION OF THE NON-ESSENTIAL AMINO ACID TYROSINE AS A REGULATOR OF THE BODY WEIGHT OF ANIMALS BY REGULATING THE APPETITE OF THE ANIMALS OR THEIR FOOD INTAKE

The invention develops a weight management system which comprises administering tyrosine in the desired amount to change and maintain the body weight of an animal. If the animal is overweight, the animal would be fed a low level tyrosine food composition. If the animal is underweight, the animal would be fed a high level tyrosine food composition. The invention also relates to an low tyrosine animal food which contains, on dry matter basis: (a) from about 0.01% to less than about 0.4% of tyrosine, (b) from about 0.42% to about 3% of phenylalanine (c) from about 7% to about 70% of protein, (d) from about 1% to about 60% of fat, (e) from 0 to 90% of carbohydrate, (f) from 0 to about 40% of dietary fiber, and (g) from 0 to about 15% of nutritional balancing agents.
2015 NSDUH Instrument Protocol Changes

The 2015 National Survey on Drug Use and Health (NSDUH) instrumentation protocols underwent several modifications from the protocols employed for the 2014 NSDUH. A summary of the changes for the 2015 NSDUH can be divided into three topics: (1) the computer-assisted interviewing (CAI) tablet screening instrument, (2) the CAI questionnaire, and (3) the interviewer materials.
CDC WONDER: AIDS Public Use Data

<p>The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS).  Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).</p>
Hospital Inpatient Discharges (SPARCS De-Identified): Cost Transparency: Beginning 2009

This dataset contains information submitted by New York State Article 28 Hospitals as part of the New York Statewide Planning and Research Cooperative (SPARCS) and Institutional Cost Report (ICR) data submissions.  The file contains information on the volume of discharges, All Payer Refined Diagnosis Related Group (APR-DRG), the severity of illness level (SOI), medical or surgical classification the median charge, median cost, average charge and average cost per discharge.
National Survey on Drug Use and Health (NSDUH-2008)

<p>The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. Detailed NSDUH 2008 documentation <a href="http://www.samhsa.gov/data/2k12/NSDUH2008MRB/Index.aspx">http://www.samhsa.gov/data/2k12/NSDUH2008MRB/Index.aspx</a> is available from SAMHSA. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2008 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For this 2008 survey, Adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. A split-sample design also was included to administer separate sets of questions to assess impairment due to mental health problems. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.</p>
Compound 529982: Heptadecane, 8-butyl-9-propyl

Chemical compound data from PubChem database. IUPAC Name: 8-butyl-9-propylheptadecane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528245: Thiophene, 2-butyl-5-ethenyl

Chemical compound data from PubChem database. IUPAC Name: 2-butyl-5-ethenylthiophene. Molecular Formula: C10H14S. Molecular Weight: 166.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NYTD Technical Bulletin #5: Cohort Management and Sampling

This TB describes how ACF will identify and finalize each cohort of youth in the NYTD follow-up population (or follow-up population sample for those States that opt to sample) for the purposes of assessing States' compliance with NYTD data collection and reporting requirements. The TB also specifies how States may opt to sample the baseline population for the purposes of collecting information on the follow-up population.

Metadata-only record linking to the original dataset. Open original dataset below.
Cumulative Influenza Vaccination Coverage by Race/Ethnicity and Age Group, NIS-ACM (Archived)

Cumulative Influenza Vaccination Coverage Age Group, Race/Ethnicity, and Jurisdiction, Adults 18 Years and Older, United States, National Immunization Survey Adult COVID Module.

The National Immunization Survey-Adult COVID Module (NIS-ACM) was launched in April 2021 among adults 18 years and older. The survey was used to monitor COVID-19 vaccination uptake and confidence in vaccination among adults and included questions about influenza vaccination.
Persistence of SARS-CoV-2 on N95 filtering facepiece respirators: implications for reuse

In response to the shortage of N95® filtering facepiece respirators (FFRs) for healthcare workers during the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) issued strategies for extended use and limited reuse of N95 FFRs to conserve supply. Previously worn N95 FFRs can serve as a source of pathogens, which can be transferred to the wearer while doffing and donning a respirator when practicing reuse. To reduce the risk of self-contamination when donning and doffing reused FFRs, the CDC suggested storing FFRs for five days between uses to allow for the decay of viable pathogens including SARS-CoV-2. This study assessed the persistence of the SARS-CoV-2 strain USA-WA1/2020 on N95 FFRs under controlled storage conditions for up to five days to inform the CDC guidance.
Compound 529226: Trimethylsilyl 6-(bis(trimethylsilyl)amino)hexanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 6-[bis(trimethylsilyl)amino]hexanoate. Molecular Formula: C15H37NO2Si3. Molecular Weight: 347.71. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Ambulatory Medical Care Survey: Electronic Medical Records Supplement, 2008-2011, Restricted

The National Electronic Health Records Survey (NEHRS) is an annual survey of non-federally employed, office-based physicians practicing in the United States (excluding those in the specialties of anesthesiology, radiology, and pathology). NEHRS began in 2008 and was originally designed as an annual mail supplement to the National Ambulatory Medical Care Survey (NAMCS). Prior to 2012, NEHRS was a supplement to the NAMCS, referred to as the NAMCS Electronic Medical Records Supplement. The annual data collected was similar to NEHRS and may be analyzed as a distinct dataset.
Data from the supplement can be used to produce state and national estimates of EHR adoption and capabilities, burden associated with EHRs, and progress physicians have made towards meeting the policy goals of the HITECH Act. 
Please refer to the following link for the 2008—2011 NAMCS Electronic Medical Records Supplemental questionnaire and data dictionary: https://www.cdc.gov/nchs/nehrs/questionnaires.htm.
Patent AT-E400986-T1: [Translated] METHOD FOR FORMING TRACKS AND TRACK ARRANGEMENTS

Printed circuit board or other tracks are formed by the deposition of liquid to form dots on a substrate from nozzles mutually spaced by a distance s. A set of n dot diameters D<SUB>i</SUB>=2 s(1/2+i/n), is used to produce linear tracks at one or more directions with respect to an axis X; each track having a minimum track width T<SUB>w</SUB>=s(n-2)/n; and the minimum spacing of tracks along the axis X being T<SUB>s</SUB>=s/n.
QHP Landscape Instructions PY2022 Individual Dental

The Dental Individual Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to consumers in the individual market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Lidocaine and prilocaine

Lidocaine and Prilocaine is a prescription topical cream containing 2.5% lidocaine and 2.5% prilocaine, used as a local anesthetic to numb the skin before minor procedures like injections or skin surgeries. Manufactured by Alembic Pharmaceuticals Inc., it's available in 5g and 30g tubes. This information was generated using AI and is provided for informational and research purposes only.